How the Amalgamation of Biosimilar Monoclonal Antibody Has Revolutionized the Healthcare Industry

Nowadays, chronic diseases are attacking individuals irrespective of age. Biosimilar monoclonal antibodies are biological drugs that can offer real value to biomedical research by giving a cost-effective option for identifying and analyzing specific disease targets in critical fields. Due to their enhanced effectiveness, these drugs are highly beneficial for performing research in various fields, such as, immuno-oncology, autoimmunity, and inflammatory diseases. This blog includes the factors shaping the biosimilar monoclonal antibody market, such as the beneficial applications of biosimilar mAbs, product launches, and the involvement of leading companies in the industry.

Diverse applications of biosimilar mAbs:

The role of biosimilar mAbs in oncology has steadily expanded over the past few years. Biosimilar mAbs are used as drugs to naturally boost the immune system of a patient suffering from cancer by binding the antigens on the surface of the cancer cells. These drugs have been approved for treating different types of cancers, including breast cancer, chronic lymphocytic leukemia, head, and Hodgkin’s lymphoma, lung cancer, and many others. Biosimilar mAb namely, Trastuzumab, is a proven biosimilar that has effectively managed the HER2-positive breast cancer among millenials. 

Furthermore, autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and connective tissue diseases, have long been managed with monoclonal antibodies. Biosimilar mAbs have brought more affordable and comprehensive treatment options for autoimmune patients. In addition, biosimilar mAbs have contributed a promising role in treating several neurological disorders, such as multiple sclerosis, epilepsy, brain tumors, neuromuscular disorders, and many more. These emerging uses of biosimilar monoclonal antibodies have created excellent investment opportunities for the market.

In the approaching years, the biosimilar monoclonal antibody market is predicted to observe significant growth owing to the rising prevalence of breast cancer among individuals worldwide. In addition, the increasing demand for effective targeted therapy among patients suffering from several chronic diseases is further fostering the market’s growth. The market is envisioned to rise at a stunning CAGR of 22.2% over the estimated timeframe from 2023 to 2032. 

Product launches:

To cater to the increasing pervasiveness of cancers among individuals globally, several leading companies have made beneficial product launches. A notable example is the launch of Vegzelma®, a biosimilar to Avastin®, by Hikma Pharmaceuticals PLC, a leading pharmaceutical company in partnership with Celltrion Healthcare Co., Ltd, a well-established biopharmaceutical company. It is an important biosimilar for oncology that would help enhance patients’ access to critical medication across the U.S.

Mergers and acquisitions:

The biosimilar monoclonal market has also seen many strategic alliances between leading market players, safeguarding the competitiveness scenario. For example, Biocon Biologics Ltd., a leading biopharmaceutical company announced its acquisition of Viatris Inc., an American-based pharmaceutical and healthcare corporation. With this acquisition, the companies aimed to promote manufacturing and commercialization of life-saving biologics medicines for patients struggling with critical diseases.

In summary, the biosimilar monoclonal market is experiencing remarkable growth in the coming years due to the surging development of cost-effective biosimilar mAbs for cancer. Furthermore, the increasing government initiatives for chronic diseases such as autoimmune diseases, blood disorders, and neurological diseases may reshape the market with greater opportunities. 

Related Post